Chronic Lymphocytic Leukemia
Specialty Channel

Featured Article
Dr Byrd shares results from a phase 3 trial on acalabrutinib versus ibrutinib for patients with CLL. These data are being presented at the 2021 ASCO Annual Meeting.
According to study findings presented at the 2021 ASCO Annual Meeting, patients with CLL are at an increased risk for herpes zoster when factoring in age and treatment regimens.
Prognostic biomarker testing rates for patients with CLL and SLL is low, indicating the need for more comprehensible treatment options, according to data presented at the virtual ONS Congress.
True or False: Venetoclax plus obinutuzumab was found to be a more effective treatment than chlorambucil plus obinutuzumab in previously untreated chronic lymphocytic leukemia.
Follow-up results from the phase 3 CLL14 trial found venetoclax plus obinutuzumab was found to be a more effective treatment than chlorambucil plus obinutuzumab in previously untreated chronic…
True or False: When Bruton's tyrosine kinase is inducted, it activates phospholipase C and calcium mobilization.
In order to survive, chronic lymphocytic leukemia cells heavily depend on microenvironmental _________ cells.
Study findings suggest that pathways regulating redox homeostasis are suitable therapeutic targets that can overcome microenvironmental protection of CLL cells.
A study comparing acalabrutinib with idelalisib plus rituximab and bendamustine plus rituximab showed that acalabrutinib yields a higher PFS rate in relapsed/refractory CLL.

News

Cirmtuzumab in combination with ibrutinib is a well-tolerated and active regimen for patients with b-cell lymphoid malignancies.
According to study findings presented at the 2021 ASCO Annual Meeting, patients with CLL are at an increased risk for herpes zoster when factoring in age and treatment regimens.
Prognostic biomarker testing rates for patients with CLL and SLL is low, indicating the need for more comprehensible treatment options, according to data presented at the virtual ONS Congress.
Follow-up results from the phase 3 CLL14 trial found venetoclax plus obinutuzumab was found to be a more effective treatment than chlorambucil plus obinutuzumab in previously untreated chronic…

Interactive Features

True or False: Venetoclax plus obinutuzumab was found to be a more effective treatment than chlorambucil plus obinutuzumab in previously untreated chronic lymphocytic leukemia.
True or False: When Bruton's tyrosine kinase is inducted, it activates phospholipase C and calcium mobilization.
In order to survive, chronic lymphocytic leukemia cells heavily depend on microenvironmental _________ cells.
True or False: CD19 CAR T cells with concurrent ibrutinib for relapsed or refractory chronic lymphocytic leukemia were well tolerated, with low CRS severity, and led to high rates of MRD-negative…
Stay in the know.
OncNet Newsletter